Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$149.56 USD

149.56
98,681

-0.40 (-0.27%)

Updated Aug 16, 2024 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

BD's (BDX) New Research Tool to Aid Single-Cell Analysis

BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.

Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.

Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices

Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Are Medical Stocks Lagging DaVita (DVA) This Year?

Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

Here's Why You Should Retain Inari Medical (NARI) for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

Ecolab's (ECL) focus on research and development raises optimism about the stock

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow

GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.

GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities

GE HealthCare's (GEHC) latest successful first installation and clinical cases using the OmnifyXR are likely to improve clinical and operational outcomes for both patients and clinicians.

Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments

Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.

Should Value Investors Buy DaVita (DVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Humana's (HUM) CenterWell Expands in Louisiana With New Centers

Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.

McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands

DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.